The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Open accessAbstract
Key Points: Rd continuous significantly extended OS compared with MPT and resulted in comparable OS to that with Rd18 in patients with multiple myeloma. Patients achieving complete or very good partial response with Rd benefited greatly from continuous vs fixed treatment in terms of PFS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation.”
From Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma (2019) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationLenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationDaratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445
Self-citationCarfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citationElotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citationOral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B. W., Jackson, S. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516282 · Cited by 1,060
Self-citationDurie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908
Self-citation
Cited by
Sorted by citations
Items 201–269 of 269
Metachronous chronic myeloid leukaemia occurring with background multiple myeloma
Yeung, J., & Khoo, L. (2020) · Pathology · doi:10.1016/j.pathol.2020.01.679 · Cited by 2
Current and future perspectives of maintenance therapy in multiple myeloma
Nagarajan, C., Tan, M. S. Y., Chen, Y., Martinelli, G., & Cerchione, C. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.20.04117-8 · Cited by 2
Charliński, G., Vesole, D. H., & Jurczyszyn, A. J. (2022) · Nowotwory Journal of Oncology · doi:10.5603/njo.a2022.0031 · Cited by 1
Risk of exposure of patients’ family members to lenalidomide at home
Takahashi, Y., Nagamine, A., Kaneta, A., Yashima, H., Obayashi, K., Araki, T., & Yamamoto, K. (2023) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2022-003632 · Cited by 1
Proceedings from the First Onco Summit: LATAM Chapter, 19–20 May 2023, Rio de Janeiro, Brazil
Hungria, V., Sureda, A. M., Campelo, G., Salvino, M. A., & Ramasamy, K. (2024) · Cancers · doi:10.3390/cancers16173063 · Cited by 1
The challenge of non-transplant eligible, newly diagnosed multiple myeloma
Ntanasis‐Stathopoulos, I., Solia, E., Filippatos, C., Gavriatopoulou, M., & Terpos, E. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2513676 · Cited by 1
Bringhen, S., Cani, L., Giuliani, N., Mangiacavalli, S., Benevolo, G., Antonioli, E., Zambello, R., Ria, R., Vincelli, I. D., Ronconi, S., et al. (2025) · Haematologica · doi:10.3324/haematol.2025.287510 · Cited by 1
Rees, M. J., & Quach, H. (2025) · Cancers · doi:10.3390/cancers17152579 · Cited by 1
Systchenko, T., Nsiala, L., Bobin, A., Gardeney, H., Motard, C., Olivier, G., Borde, F., Corby, A., Roul, C., Fleck, E., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016625 · Cited by 1
Self-citationHow to approach the high-risk myeloma from induction through relapse?
Weisel, K. C., Schaefers, C., & Leypoldt, L. B. (2025) · Hematology · doi:10.1182/hematology.2025000762 · Cited by 1
Self-citationGoede, V. (2020) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-020-01701-w · Cited by 1
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma
Bobin, A., Kyheng, M., Guidez, S., Gruchet, C., Richez, V., Duhamel, A., Karlin, L., Kolb, B., Tiab, M., Araujo, C., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01415-x · Cited by 1
Self-citationLeidy, S. B., Hull, L. R., Macik, M. R., Gonzalvo, J. D., & Weddle, K. J. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211053248 · Cited by 1
Ludwig, W.-D., Ganser, A., & Maschmeyer, G. (2021) · Springer eBooks · doi:10.1007/978-3-662-63825-5_35 · Cited by 1
Tamai, K., Hirose, H., Akazawa, Y., Yoshikawa, Y., Nomura, M., Takeyama, H., Tokunaga, M., Tei, M., Okamura, S., & Akamaru, Y. (2024) · Surgical Case Reports · doi:10.1186/s40792-024-01838-5 · Cited by 1
Li, Z., Zhang, W., Huang, F., & Hao, S. (2025) · Clinics · doi:10.1016/j.clinsp.2025.100575 · Cited by 1
Landgren, O., Biran, N., O’Donnell, E., Mikhael, J. R., Weisel, K. C., Broijl, A., Usmani, S. Z., Moreau, P., Gay, F., Mina, R., et al. (2025) · HemaSphere · doi:10.1002/hem3.70178 · Cited by 1
Self-citationPrimärtherapie beim Multiplen Myelom
Breitkreutz, I., Raab, M., & Goldschmidt, H. (2018) · Der Internist · doi:10.1007/s00108-018-0527-x · Cited by 2
Yokoyama, A., Kada, A., Saito, A. M., Sawamura, M., Komeno, T., Sunami, K., & Takezako, N. (2019) · PubMed · doi:10.18926/amo/57722 · Cited by 1
Advances & future prospects in newly diagnosed multiple myeloma patients
Hamadeh, I. S., Atrash, S., Fisher, A. M., Khan, M., Robinson, J., Paul, B., & Usmani, S. Z. (2020) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.96 · Cited by 1
Recommendations on the management of multiple myeloma in 2020
Vekemans, M., Doyen, C., Caers, J., Wu, K., Kentos, A., Mineur, P., Michaux, L., Delforge, M., & Meuleman, N. (2020) · Acta Clinica Belgica · doi:10.1080/17843286.2020.1860411 · Cited by 1
Self-citationKomuro, M., Furuya, T., Ohashi, Y., Watabe, D., Nomura, H., Komuro, A., Tabei, A., Sawamura, S., Hyakutake, H., Kusu, H., et al. (2021) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100727 · Cited by 1
Анатольевна, Ж. В., Vorobyev, V. I., Гемджян, Э. Г., Ulyanova, M. A., Валерьевич, Ч. М., Ivanova, V. L., Vinogradova, O., & Ptushkin, V. V. (2021) · Terapevticheskii arkhiv · doi:10.26442/00403660.2021.07.200956 · Cited by 1
The evolving role and utility of off-label drug use in multiple myeloma
Stoeckle, J. H., Davies, F. E., Williams, L. S., Boyle, E. M., & Morgan, G. J. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00050 · Cited by 1
Self-citationMultiple Myeloma with a Special Focus on Precision Medicine
Schmidt, A. (2020) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2020.06.023 · Cited by 2
Krishnan, A. Y., Nathwani, N., Amanam, I. U., & Gupta, R. (2019) · Springer eBooks · doi:10.1007/978-3-030-31471-2_5 · Cited by 1
Ćojbašić, I., Vučić, M., Tijanić, I., & Ćojbašić, Ž. (2022) · Sao Paulo Medical Journal · doi:10.1590/1516-3180.2021.0174.r2.22062021 · Cited by 1
Yokoyama, A., Kada, A., Kagoo, T., Hidaka, M., Iida, H., Miyata, Y., Saito, A. M., Sawamura, M., Komeno, T., Sunami, K., et al. (2022) · PubMed Central · doi:10.18999/nagjms.84.1.80 · Cited by 1
Lahoud, O. B., Landau, H. J., Nguyen, J., Devlin, S. M., Lendvai, N. K., Weltz, J., Ayorinde, T., Chung, D. J., Lesokhin, A. M., Kewalramani, T., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2062347 · Cited by 1
Facon, T. T. F., & Manier, S. (2022) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2022.07.006 · Cited by 1
Self-citationSuzuki, K., & Yano, S. (2023) · Life · doi:10.3390/life13112229 · Cited by 1
From little subclones grow mighty oaks
Boyle, E. M., & Davies, F. E. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00727-w · Cited by 1
Self-citationGentle yet effective combination therapy with novel agents in elderly multiple myeloma patients
Larocca, A., D’Agostino, M., & Boccadoro, M. (2018) · British Journal of Haematology · doi:10.1111/bjh.15260
Update of clinical highlights presented at the 2017 American Society of Hematology Meeting
Burger, S., Zojer, N., & Ludwig, H. (2018) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-018-0407-z
Self-citationTherapie des multiplen Myeloms bei älteren Patienten
Weyermann, C., Thorspecken, S., & Straka, C. (2018) · Info Onkologie · doi:10.1007/s15004-018-5941-7
Onishi, Y., Yokoyama, H., Katsuoka, Y., Ito, T., Kimura, T., Yamamoto, J., Nakajima, S., Sasaki, O., Ara, T., Minauchi, K., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04240-x
Treatment of Multiple Myeloma with Kidney Involvement
Cook, M. A. (2021) · Springer eBooks · doi:10.1007/978-3-030-63662-3_10
Abdallah, M. M., McEllistrim, C., Kumar, A. J., & Loh, K. P. (2021) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2021.02.010
Cheong, C. S., Aziz, T. A. H. T. K., Anuar, N. A., chong, B., Chin, E. F. M., Khairullah, S., Liong, C. C., & Gan, G. G. (2021) · doi:10.22541/au.161789033.39632939/v1
Maintenance Strategies for Myeloma
Nooka, A. K., & Joseph, N. S. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000524
Up-front ixazomib in older patients with myeloma
Harousseau, J., & Mohty, M. (2021) · Blood · doi:10.1182/blood.2021011262
Self-citationNakagawa, M., Iriyama, N., Ishikawa, T., Miura, K., Uchino, Y., Takahashi, H., Hamada, T., Iizuka, K., KOIKE, T., Kurihara, K., et al. (2021) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10030
Armoiry, X., Aulagner, G., & Henaine, A.-M. (2020) · Elsevier eBooks · doi:10.1016/b978-2-294-76375-5.00026-9
d’Epinay, M. L., Güsewell, S., Graf, N., Mey, U., Driessen, C., & Hitz, F. (2022) · Hematological Oncology · doi:10.1002/hon.3024
Updates on Multiple Myeloma: What’s New in Risk Stratification, Treatment, and Prognosis
Mutahar, E. Y. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106159
Yee, A. J., Hideshima, T., Raje, N. S., & Anderson, K. C. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm122.pub2
Self-citationFranz, J. K., & Lonial, S. (2022) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2022.18.2.96
Hämatologische Neoplasien und solide Tumore
Ludwig, W.-D., Ganser, A., & Maschmeyer, G. (2022) · Springer eBooks · doi:10.1007/978-3-662-66303-5_5
Recent advances in the treatment of multiple myeloma
Jung, S. (2023) · Journal of Korean Medical Association · doi:10.5124/jkma.2023.66.4.245
Wang, Y., Yang, Y., Wang, W., Li, J., Xu, T., & Liu, P. (2023) · Research Square · doi:10.21203/rs.3.rs-2941538/v1
Zabolotneva, Y. A., & Сергеевич, К. И. (2024) · Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice · doi:10.37489/2588-0519-2023-4-40-51
II. Current Treatment Strategies for Multiple Myeloma in Japan
Shimura, Y. (2023) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.112.1195
Mikala, G., Ceglédi, A., & Szemlaky, Z. (2024) · Hematológia–Transzfuziológia · doi:10.1556/2068.2024.00194
Hämatologische Neoplasien und solide Tumore
Ludwig, W.-D., Ganser, A., & Maschmeyer, G. (2025) · Springer eBooks · doi:10.1007/978-3-662-70594-0_5
CDA-AMC (2025) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2025.1228
Suzuki, K., Ito, M., Sakai, C., Tsuchiya, H., Wu, D. B., & Koroki, Y. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2590840
Jungová, A., Štork, M., Špıčka, I., Radocha, J., Minařík, J., Pavlíček, P., Mihályová, J., Pour, L., Štraub, J., Maisnar, V., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.10.022
Eisfeld, C., Kajüter, H., Möller, L., Wellmann, I., Shumilov, E., & Stang, A. (2024) · Figshare · doi:10.6084/m9.figshare.26580806
Sim, S., McCaughan, G. J. B., Zannettino, A. C. W., Ho, P. J., Joshua, D., Talaulikar, D., Mollee, P. N., Prince, H. M., Spencer, A. G., Harrison, S. J., et al. (2026) · Internal Medicine Journal · doi:10.1111/imj.70329
Lee, J. Y., Choi, S., Jung, S., Park, S., Kim, J. S., Shin, S., Jeon, Y., Yahng, S., Lee, J.-J., Kim, H. J., et al. (2026) · Annals of Hematology · doi:10.1007/s00277-026-06849-w
Self-citationNückel, H., Behlendorf, T., Schulz, H., Schulze, M. B., Schardt, C., Medinger, T., Koenigsmann, M., Dechow, T. N., Indorf, M., Bürkle, D., et al. (2026) · Cancer Medicine · doi:10.1002/cam4.71758
The genetic architecture of plasma cell disorders
Boyle, E. M. (2020) · theses.fr (ABES) · doi:10.70675/404c872dz0ef2z4f8eza81fz592360ed443b
Self-citationDe-escalation trials in multiple myeloma: past, present and future
Mian, H. S., Costa, L. J., Mohty, M., Garfall, A. L., & Rajkumar, S. V. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01186-3
Self-citationImai, Y., Handa, T., & Mitani, K. (2023) · Institutional Repositories DataBase (IRDB)
Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making
Bazarbachi, A. H., Lentzsch, S., Facon, T. T. F., Harousseau, J., & Mohty, M. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00545
Self-citationLee, J. H., Kim, S., Kım, K., Ashrafi, E., Wellard, C. J., Moore, E., Chng, W. J., Chen, W., Gan, G. G., Ho, P. J., et al. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70318
Self-citation
Metadata
- Authors
- Facon, T., Dimopoulos, M. A., Dispenzieri, A., Catalano, J. V., Belch, A., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N. J., Banos, A., Tiab, M., Delforge, M., Cavenagh, J. D., Geraldes, C., Lee, J.-J., Chen, C., Oriol, A., De La Rubia, J., White, D., Binder, D., Lu, J., Anderson, K. C., Moreau, P., Attal, M., Perrot, A., Arnulf, B., Qiu, L., Roussel, M., Boyle, E., Manier, S., Mohty, M., Avet-Loiseau, H., Leleu, X., Ervin-Haynes, A., Chen, G., Houck, V., Benboubker, L., & Hulin, C.
- Affiliations
- Hôpital Claude Huriez (FR)
- National and Kapodistrian University of Athens (GR)
- Mayo Clinic (US)
- Frankston Hospital (AU)
- Cross Cancer Institute (CA)
- Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy;
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- University of Tübingen (DE)
- Wilhelminen Hospital (AT)
- University of Calgary (CA)
- Centre Hospitalier de la Côte Basque (FR)
- Department of Hematology, University Hospital, La Roche Sur Yon, France;
- Universitair Ziekenhuis Leuven (BE)
- National Health Service (GB)
- Unidade Local de Saúde de Coimbra (PT)
- Chonnam National University Hwasun Hospital (KR)
- Princess Margaret Cancer Centre (CA)
- Josep Carreras Leukaemia Research Institute (ES)
- Hospital Dr. Peset, Valencia, Spain;
- Queen Elizabeth II Health Sciences Centre (CA)
- Kantonsspital Winterthur (CH)
- Peking University People's Hospital (CN)
- Dana-Farber Cancer Institute (US)
- Université de Nantes (FR)
- Institut universitaire du cancer de Toulouse Oncopole (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Hôpital Saint-Louis (FR)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Hôpital Saint-Antoine (FR)
- Unite de Genomique du Myelome, Centre Hospitalier Universitaire Rangueil, Toulouse, France;
- Inserm (FR)
- Celgene (United States) (US)
- Centre Hospitalier Universitaire de Tours (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- ORCID
- Facon, Thierry
- Dimopoulos, Meletios A.
- Dispenzieri, Angela
- Belch, Andrew
- Weisel, Katja
- Ludwig, Heinz
- Bahlis, Nizar J.
- Banos, Anne
- Delforge, Michel
- Geraldes, Catarina
- Lee, Je-Jung
- Chen, Christine
- Oriol, Albert
- White, Darrell
- Lu, Jin
- Anderson, Kenneth C.
- Moreau, Philippe
- Attal, Michel
- Perrot, Aurore
- Arnulf, Bertrand
- Qiu, Lugui
- Roussel, Murielle
- Boyle, Eileen
- Manier, Salomon
- Mohty, Mohamad
- Leleu, Xavier
- Chen, Guang
- Benboubker, Lotfi
- Hulin, Cyrille
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2018-01-18
- Volume
- 131
- Issue
- 3
- Pages
- 301-310
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC5774211
- OpenAlex
- W2769593282
- Cited by
- 271
- References
- 23
- Citations by year
- 2026: 8 · 2025: 22 · 2024: 15 · 2023: 31 · 2022: 36 · 2021: 43 · 2020: 48 · 2019: 40 · 2018: 27
- FWCI
- 24.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- Celgene
- National Cancer Institute (P50CA186781)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- multiple myeloma, transplant-ineligible multiple myeloma, lenalidomide, bortezomib, second-line therapy, survival outcomes, time to next treatment, complete response, secondary malignancies, FIRST trial
- MeSH terms
- Progression-Free Survival, Antineoplastic Agents, Humans, Multiple Myeloma, Survival Analysis, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
